Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydralazine and magnesium valproate plus topotecan in cisplatin-resistant ovarian cancer
NCT00533299Phase 3Unknown
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydralazine, magnesium valproate in ovarian cancer, sponsored by Instituto Nacional de Cancerología. Status: unknown.
02
Drugs
hydralazinemagnesium valproate
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00533299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533299.